Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03992170 | Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive(DART4MM) | unknown | Phase 2 | 50 | Azienda Ospedaliera Universitaria SeneseOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT03931421 | B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 4, 2019 |
| clinicaltrials |
| NCT03777085 | Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) | unknown | Phase 3 | 230 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 30, 2019 | clinicaltrials |
| NCT03751293 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 10 | Hebei Yanda Ludaopei HospitalOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT03940833 | Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM | unknown | Phase 1 / Phase 2 | 20 | Asclepius Technology Company Group (Suzhou) Co., Ltd.INDUSTRY | 1 | May 7, 2019 | clinicaltrials |
| NCT03588598 | Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies | unknown | Phase 1 | 40 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Apr 30, 2019 | clinicaltrials |
| NCT02747732 | Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL | unknown | Phase 2 | 72 | Meirav Kedmi MDOTHER_GOV | 1 | Apr 23, 2019 | clinicaltrials |
| NCT03185494 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT02652910 | Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma(MeCAR) | unknown | Phase 1 / Phase 2 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03093168 | BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma | unknown | Phase 1 | 10 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT01670370 | Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL. | unknown | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Feb 15, 2019 | clinicaltrials |
| NCT01240525 | Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers(ProT4) | unknown | Phase 2 | 114 | University College, LondonOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT00863460 | Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients(PRECIS) | unknown | Phase 2 | 140 | Institut CurieOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT02767674 | Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma | unknown | Phase 3 | 258 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03697655 | Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma(PREDATOR) | unknown | Phase 2 | 274 | Polish Myeloma ConsortiumOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03792620 | Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation(MAXDARA) | unknown | Phase 3 | 20 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03776331 | Vascular Functions in Myeloma Patients During Anti-tumor Therapy | unknown | — | 96 | University Hospital, EssenOTHER | 0 | Dec 19, 2018 | clinicaltrials |
| NCT03672253 | CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma | unknown | Phase 1 | 20 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 14, 2018 | clinicaltrials |
| NCT03674463 | LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma | unknown | Phase 1 | 10 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 14, 2018 | clinicaltrials |
| NCT03767725 | Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma | unknown | Phase 1 | 10 | Shenzhen Second People's HospitalOTHER | 1 | Dec 10, 2018 | clinicaltrials |
| NCT03767751 | A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT03346642 | Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT03746652 | Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma(DARIA) | unknown | Phase 2 | 50 | Hellenic Society of HematologyOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT03601624 | Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans(MM-POM-2018) | unknown | Phase 2 | 18 | Instituto de Seguridad y Servicios Sociales de los Trabajadores del EstadoOTHER_GOV | 1 | Nov 14, 2018 | clinicaltrials |
| NCT03679455 | A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1(OBI-1) | unknown | Phase 2 | 30 | Polish Myeloma ConsortiumOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT03733327 | BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 20 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT03719989 | Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma(EPIC) | unknown | Phase 2 | 27 | Seoul National University HospitalOTHER | 1 | Oct 25, 2018 | clinicaltrials |
| NCT03706547 | Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM | unknown | Phase 1 | 20 | Peng LiuOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT03704597 | Cryotherapy Against Oral Mucositis After High-dose Melphalan | unknown | N/A | 100 | Sahlgrenska University HospitalOTHER | 0 | Oct 15, 2018 | clinicaltrials |
| NCT03579082 | A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma | unknown | Phase 4 | 60 | Mingzhi ZhangOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03661554 | BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma(BCMA CAR-T) | unknown | Early Phase 1 | 15 | The Pregene (ShenZhen) Biotechnology Company, Ltd.INDUSTRY | 1 | Sep 10, 2018 | clinicaltrials |
| NCT02187731 | Functional Imaging in Multiple Myeloma -PET/CT and Diffusion Weighted Imaging in Multiple Myeloma(FULIMA) | unknown | — | 70 | Odense University HospitalOTHER | 1 | Aug 29, 2018 | clinicaltrials |
| NCT02572492 | Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support(CARFI) | unknown | Phase 2 | 200 | Henrik GregersenOTHER | 5 | Aug 17, 2018 | clinicaltrials |
| NCT03201471 | Chidamide With R-CHOP Regimen for DLBCL Patients(DLBCL) | unknown | Phase 2 | 39 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT03605056 | Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM | unknown | Phase 2 | 25 | Peng LiuOTHER | 1 | Jul 30, 2018 | clinicaltrials |
| NCT03559764 | Study of BCMA CAR-T in Multiple Myeloma | unknown | Early Phase 1 | 20 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jun 18, 2018 | clinicaltrials |
| NCT03556748 | WB-EMS and Nutrition in Patients With Hematological Malignancies | unknown | N/A | 40 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Jun 14, 2018 | clinicaltrials |
| NCT01554852 | Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients(Myeloma XI) | unknown | Phase 3 | 4,420 | University of LeedsOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT02158702 | Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib | unknown | Phase 2 | 100 | National University Hospital, SingaporeOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT03515915 | Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment | unknown | — | 30 | University Hospital, MontpellierOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT02559154 | Modified Bortezomib-based Combination Therapy for Multiple Myeloma | unknown | Phase 4 | 80 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT03513601 | Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma | unknown | Phase 4 | 20 | Mingzhi ZhangOTHER | 1 | May 1, 2018 | clinicaltrials |
| NCT02991638 | Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers | unknown | Phase 3 | 62 | The University of Hong KongOTHER | 1 | Apr 12, 2018 | clinicaltrials |
| NCT02955810 | Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)(CyBorD-Dara) | unknown | Phase 1 | 18 | National University of Ireland, Galway, IrelandOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT03475628 | Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma(REBUILD) | unknown | Phase 2 | 57 | Hellenic Society of HematologyOTHER | 1 | Mar 23, 2018 | clinicaltrials |
| NCT01862445 | Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients | unknown | — | 100 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT01792102 | Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma | unknown | Phase 1 / Phase 2 | 38 | OncotherapeuticsINDUSTRY | 1 | Mar 5, 2018 | clinicaltrials |
| NCT02354313 | Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients(MCL0208) | unknown | Phase 3 | 300 | Fondazione Italiana Linfomi - ETSOTHER | 2 | Feb 9, 2018 | clinicaltrials |
| NCT03417414 | Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases? | unknown | — | 160 | Ottawa Hospital Research InstituteOTHER | 0 | Feb 7, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jun 20, 2019source: clinicaltrials